Title: Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon ...

The North Central London expansion will bring HealthTab™ to even more patients, with a continued focus on underserved populations and reducing health disparities. By expanding access to preventative ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such ...

The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.

The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

In this role, Brendan will oversee revenue growth across Marble and its flagship applications Medchart and SettLiT, deepening customer relationships and scaling go-to-market efforts as demand for ...

Goldman Sachs & Co. LLC and Guggenheim Securities are acting as the joint book-running managers for the proposed public offering.

Morgan Stanley, BofA Securities, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. Canaccord Genuity and Citizens Capital Markets are acting as lead ...

The HEMAcollect™●PROTEIN BCT, powered by ProteoPrecision™ technology, minimizes hemolysis and activation of platelets, ensuring the sample accurately reflects the body’s state at collection. It is ...

The reverse stock split was approved by Passage Bio’s stockholders, at the Company’s 2025 annual meeting of stockholders held on May 28, 2025, to be effected at the Board’s discretion within approved ...

CAMBRIDGE, Royaume-Uni et MONTRÉAL, 10 juill. 2025 (GLOBE NEWSWIRE) -- Epitopea, société transatlantique d'immunothérapie anticancéreuse développant des immunothérapies à base d'ARN accessibles et prê ...